In this manuscript, we will discuss the aberrant signal transduction pathways altered by mutations in ACVR1/ALK2 and briefly review the existing in vitro platforms to screen for novel drugs and genes with therapeutic potential in FOP. This evidence concerns the gene ACVR1 and fibrodysplasia ossificans progressiva.